Sign up Australia
Proactive Investors - Run By Investors For Investors

Immuron concludes promising fatty liver disease clinical study

The company will report top line clinical trial results in Q1 2018.
model of a liver
The study enrolled 133 patients

Immuron Ltd (ASX:IMC, NASDAQ:IMRN) has concluded the phase II study of IMM‐124E for the treatment of NASH (non-alcoholic steatohepatitis), with the results expected in Q1 2018.

NASH is also known as non-alcoholic fatty liver disease.

The last patient in the clinical study conducted the final scheduled visit on October 9, following a 28‐week study period. The study enrolled a total of 133 patients with biopsy‐proven NASH.

On October 18, the study site conducted its close‐out visit.

This effectively concludes patient dosing and research activities at all study sites for the Phase II study. 

Immuron will report its top line clinical trial results in Q1 of calendar year 2018, once all data is finalised and reviewed by the company and its scientific advisory board.

Once reported, Immuron will continue its partnering and business development efforts to reach the next phase of clinical studies.

In July 2017, the company revealed interim analysis results, in which IMM‐124 demonstrated a statistically‐significant reduction in two enzymes found in the liver, compared to the placebo.

These preliminary results suggested a reduction in liver injury over the duration of treatment compared to the placebo.

View full IMC profile View Profile

Immuron Ltd Timeline

Newswire
June 08 2017
Newswire
May 30 2017

Related Articles

Cyrptocurrencies
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
Woman sneezing
September 27 2018
"We look forward to the exciting developments in our early pipeline planned for 2019, and we expect to continue to grow our European business while progressing towards US and German registration for our lead products," said company chairman, Peter Jensen
skin cream
October 25 2018
The cream is currently undergoing its first-in-human studies, with researchers assessing its skin irritancy, moisturisation potential and skin barrier function

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use